TABLE 4.
HCC‐related and overall mortality per 100,000 screened patients according to HCC annual incidence and surveillance modality and showing annual and quarterly compared to semiannual surveillance
| Annual HCC incidence | 6‐M US (ref.) | US | MRI | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12 M | 3 M | 12 M | 6 M | ||||||||||
| Deaths | Deaths | Abs. Diff | Rel. Diff. | Deaths | Abs. Diff | Rel. Diff. | Deaths | Abs. Diff | Rel. Diff. | Deaths | Abs. Diff | Rel. Diff. | |
| HCC‐related mortality | |||||||||||||
| 0.2% | 431 | 520 | +89 | +20.6% | 370 | −61 | −14.2% | 405 | −26 | −6.0% | 356 | −75 | −17.4% |
| 0.4% | 865 | 1044 | +179 | +20.7% | 742 | −123 | −14.2% | 813 | −52 | −6.0% | 715 | −150 | −17.3% |
| 1.5% | 3146 | 3799 | +653 | +20.8% | 2700 | −446 | −14.2% | 2960 | −186 | −5.9% | 2602 | −544 | −17.3% |
| Overall mortality | |||||||||||||
| 0.2% | 19,016 | 19,074 | +58 | +0.3% | 18,980 | −36 | −0.2% | 19,003 | −13 | −0.07% | 18,978 | −38 | −0.2% |
| 0.4% | 19,531 | 19,647 | +116 | +0.6% | 19,459 | −72 | −0.4% | 19,504 | −27 | −0.1% | 19,454 | −77 | −0.4% |
| 1.5% | 22,239 | 22,658 | +419 | +1.9% | 21,976 | −293 | −1.3% | 22,141 | −98 | −0.4% | 21,958 | −281 | −1.3% |
Note: Baseline case scenario relies on a tumor doubling time of 90 days.
Abbreviations: Abs., absolute; diff., difference; HCC, hepatocellular carcinoma; M, month; MRI, magnetic resonance imaging; ref., reference; US, ultrasound.